Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 9/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.88 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.88 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.88 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.88 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.88 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.88 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.88 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.88 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.88 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.88 |
| ▸ | KDR | P35968 | 11/20 | 0.79 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.79 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.79 |
| ▸ | FLT1 | P17948 | 2/20 | 0.79 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.79 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.79 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25226025 | 0.92 | PDGFRB (0.92) | MELKCHEK1PRKAB2NUAK1MAPK1 | |
| SCHEMBL26924075 | 0.88 | PDGFRB (1.00) | MELKCHEK1PRKAB2NUAK1MAPK1 | |
| SCHEMBL29379036 | 0.88 | PDGFRB (1.00) | MELKCHEK1PRKAB2NUAK1MAPK1 | |
| SCHEMBL31441440 | 0.86 | MELK (1.00) | MELKCHEK1PRKAB2NUAK1MAPK1 | |
| SCHEMBL25275137 | 0.85 | MELK (0.73) | MELKCHEK1PRKAB2NUAK1MAPK1 | |
| SCHEMBL26924080 | 0.81 | MELK (0.68) | MELKCHEK1PRKAB2NUAK1MAPK1 | |
| SCHEMBL27218206 | 0.76 | KDR (0.68) | MELKCHEK1PRKAB2NUAK1MAPK1 | |
| SCHEMBL26928451 | 0.75 | KDR (0.70) | MELKKDRPDGFRBFGFR1PDGFRA | |
| SCHEMBL26928536 | 0.74 | KDR (0.61) | MELKPRKAA1PRKAG2KDRPDGFRB | |
| SCHEMBL31120118 | 0.74 | FGFR1 (0.67) | MELKCHEK1PRKAB2NUAK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250170090-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2025-05-29 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| WO-2025043394-A1 | KIT FOR FORMING SUPRAMOLECULAR SELF-ASSEMBLY COMPLEX AND USE THEREOF | 北京睿创康泰医药研究院有限公司 | 2025-03-06 | — | — | WO | disclosed |
| EP-4470565-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | OnQuality Pharmaceuticals China Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| CN-118742325-A | Methods for preventing or treating diseases or conditions associated with antineoplastic agents | 上海岸阔医药科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| WO-2023142996-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | 上海岸阔医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116211789-A | Composition and use thereof | 上海岸阔医药科技有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170090-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | VHL, SLC10A1, NNMT | MELK 2626/4885CHEK1 4512/4885PRKAB2 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.